These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 17596512

  • 1. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
    Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, Wagberg F, Brattsand M, Hachem JP, Leonardsson G, Hovnanian A.
    Mol Biol Cell; 2007 Sep; 18(9):3607-19. PubMed ID: 17596512
    [Abstract] [Full Text] [Related]

  • 2. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
    Meyer-Hoffert U, Wu Z, Schröder JM.
    PLoS One; 2009 Sep; 4(2):e4372. PubMed ID: 19190773
    [Abstract] [Full Text] [Related]

  • 3. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
    Borgoño CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Diamandis EP.
    J Biol Chem; 2007 Feb 09; 282(6):3640-52. PubMed ID: 17158887
    [Abstract] [Full Text] [Related]

  • 4. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
    Wiegmann H, Valentin F, Tarinski T, Liebau E, Loser K, Traupe H, Oji V.
    Br J Dermatol; 2019 Nov 09; 181(5):999-1008. PubMed ID: 30801672
    [Abstract] [Full Text] [Related]

  • 5. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
    Fortugno P, Bresciani A, Paolini C, Pazzagli C, El Hachem M, D'Alessio M, Zambruno G.
    J Invest Dermatol; 2011 Nov 09; 131(11):2223-32. PubMed ID: 21697885
    [Abstract] [Full Text] [Related]

  • 6. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.
    Nin M, Katoh N, Kokura S, Handa O, Yoshikawa T, Kishimoto S.
    J Dermatol Sci; 2009 Apr 09; 54(1):17-24. PubMed ID: 19118981
    [Abstract] [Full Text] [Related]

  • 7. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
    Ishida-Yamamoto A, Deraison C, Bonnart C, Bitoun E, Robinson R, O'Brien TJ, Wakamatsu K, Ohtsubo S, Takahashi H, Hashimoto Y, Dopping-Hepenstal PJ, McGrath JA, Iizuka H, Richard G, Hovnanian A.
    J Invest Dermatol; 2005 Feb 09; 124(2):360-6. PubMed ID: 15675955
    [Abstract] [Full Text] [Related]

  • 8. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
    Fortugno P, Furio L, Teson M, Berretti M, El Hachem M, Zambruno G, Hovnanian A, D'Alessio M.
    Hum Mol Genet; 2012 Oct 01; 21(19):4187-200. PubMed ID: 22730493
    [Abstract] [Full Text] [Related]

  • 9. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.
    Bitoun E, Micheloni A, Lamant L, Bonnart C, Tartaglia-Polcini A, Cobbold C, Al Saati T, Mariotti F, Mazereeuw-Hautier J, Boralevi F, Hohl D, Harper J, Bodemer C, D'Alessio M, Hovnanian A.
    Hum Mol Genet; 2003 Oct 01; 12(19):2417-30. PubMed ID: 12915442
    [Abstract] [Full Text] [Related]

  • 10. Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type related inhibitor action and enhance its degradation.
    Ramesh K, Matta SA, Chew FT, Mok YK.
    Allergy; 2020 Feb 01; 75(2):403-411. PubMed ID: 31407378
    [Abstract] [Full Text] [Related]

  • 11. Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation.
    Miyai M, Matsumoto Y, Yamanishi H, Yamamoto-Tanaka M, Tsuboi R, Hibino T.
    J Invest Dermatol; 2014 Jun 01; 134(6):1665-1674. PubMed ID: 24390132
    [Abstract] [Full Text] [Related]

  • 12. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
    Chavarria-Smith J, Chiu CPC, Jackman JK, Yin J, Zhang J, Hackney JA, Lin WY, Tyagi T, Sun Y, Tao J, Dunlap D, Morton WD, Ghodge SV, Maun HR, Li H, Hernandez-Barry H, Loyet KM, Chen E, Liu J, Tam C, Yaspan BL, Cai H, Balazs M, Arron JR, Li J, Wittwer AJ, Pappu R, Austin CD, Lee WP, Lazarus RA, Sudhamsu J, Koerber JT, Yi T.
    Sci Transl Med; 2022 Dec 14; 14(675):eabp9159. PubMed ID: 36516271
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
    Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, Clayman GL, Jayakumar A.
    Biol Chem; 2005 Nov 14; 386(11):1173-84. PubMed ID: 16307483
    [Abstract] [Full Text] [Related]

  • 14. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S, Olt S, Schoefmann N, Stuetz A, Winiski A, Wolff-Winiski B.
    Exp Dermatol; 2014 Jul 14; 23(7):524-6. PubMed ID: 24848304
    [Abstract] [Full Text] [Related]

  • 15. LEKTI-1 in sickness and in health.
    Roelandt T, Thys B, Heughebaert C, De Vroede A, De Paepe K, Roseeuw D, Rombaut B, Hachem JP.
    Int J Cosmet Sci; 2009 Aug 14; 31(4):247-54. PubMed ID: 19467033
    [Abstract] [Full Text] [Related]

  • 16. When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition.
    Furio L, Hovnanian A.
    J Invest Dermatol; 2011 Nov 14; 131(11):2169-73. PubMed ID: 21997416
    [Abstract] [Full Text] [Related]

  • 17. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
    Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, Brattsand M, Beck IM, Sedlacek R.
    PLoS Genet; 2017 Jan 14; 13(1):e1006566. PubMed ID: 28095415
    [Abstract] [Full Text] [Related]

  • 18. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
    Sugimoto S, Morizane S, Nomura H, Kobashi M, Sugihara S, Iwatsuki K.
    J Dermatol Sci; 2018 Nov 14; 92(2):181-187. PubMed ID: 30270115
    [Abstract] [Full Text] [Related]

  • 19. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.
    Meyer-Hoffert U, Wu Z, Kantyka T, Fischer J, Latendorf T, Hansmann B, Bartels J, He Y, Gläser R, Schröder JM.
    J Biol Chem; 2010 Oct 15; 285(42):32174-81. PubMed ID: 20667819
    [Abstract] [Full Text] [Related]

  • 20. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.
    Komatsu N, Saijoh K, Jayakumar A, Clayman GL, Tohyama M, Suga Y, Mizuno Y, Tsukamoto K, Taniuchi K, Takehara K, Diamandis EP.
    J Invest Dermatol; 2008 May 15; 128(5):1148-59. PubMed ID: 17989726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.